Educational reference only. Not medical advice. Nothing on this site is for sale.
Latest
CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyTrial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialFDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesCompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeTrial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMTrial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetTrial resultFull TRIUMPH-2 retatrutide results published in The LancetFDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesWADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances
Sign in

Combination drug in development

CagriSema (cagrilintide + semaglutide)

Also called CagriSema

The only combination here that has been tested properly: a fixed-dose pairing of an amylin analog and a GLP-1 drug, made by Novo Nordisk.

What is in it

Metabolic & weightLate-stage trialsFlashcard

Cagrilintide (and CagriSema)

NN9838 · CagriSema (cagrilintide + semaglutide)

Cagrilintide is an experimental weekly shot that mimics amylin, a fullness hormone made by the pancreas.

Metabolic & weightFDA-approvedFlashcard

Semaglutide

Wegovy · Ozempic

Semaglutide is a long-acting copy of the gut hormone GLP-1.

Is there evidence for the combination?

Large phase 3 trials (REDEFINE 1 and 2) were published in 2025 1. Novo Nordisk filed for FDA approval in December 2025 2. In the open-label REDEFINE 4 trial against tirzepatide, CagriSema missed its main goal 3. It is not approved, and it cannot legally be compounded.

Weekly protocol

How the schedule looks week by week. Each chart says where it comes from: a prescribing label, a clinical trial, or a protocol commonly reported online.

Phase 2 trial in type 2 diabetes

Clinical trial

One week

D1D2D3D4D5D6D7

Once weekly · Subcutaneous injection

Syringe units (U-100)

Dose by week

0.25 mg + 0.25 mgwk 1–4
0.5 mg + 0.5 mgwk 5–8
1.0 mg + 1.0 mgwk 9–12
1.7 mg + 1.7 mgwk 13–16
2.4 mg + 2.4 mgMaintenance · wk 17–32

Supplies for one course (estimate)

Counts only. This site does not sell or link to supplies.

Course
32 weeks (16-week escalation, 16-week maintenance)
Note
Doses are cagrilintide + semaglutide, both stepped up every 4 weeks. The phase 3 REDEFINE trials used the same 2.4 mg + 2.4 mg weekly target for 68 weeks.
Source
Frias JP et al. Co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: phase 2 trial. Lancet 2023

Reference only, not a recommendation. Label and trial schedules were set for specific patients under medical supervision. Use the calculator only to understand the arithmetic.

Each ingredient at a glance

IngredientEvidenceUS FDA statusSports (WADA)
Cagrilintide (and CagriSema)Late-stage trialsInvestigational; not FDA-approved. New Drug Application for CagriSema submitted December 2025; FDA review expected in…Not named on the WADA list; as an unapproved drug it would fall under S0…
SemaglutideFDA-approvedFDA-approved: Ozempic (type 2 diabetes, 2017), Rybelsus (oral, type 2 diabetes, 2019), Wegovy injection (weight…Not prohibited. Semaglutide markers are tracked under WADA's Monitoring…

Mixing adds unknowns. A blend carries the risks of every ingredient, and the interactions are untested. Vial contents and ratios are set by sellers and are not standardized. See each ingredient page for safety and legal details.

Sources

  1. REDEFINE 1 and REDEFINE 2 journal scan (ACC; NEJM 2025)
  2. Novo Nordisk submits NDA to FDA for CagriSema (PharmExec, Dec 2025)
  3. CagriSema REDEFINE 4 head-to-head: primary endpoint not achieved